GSK: ViiV's HIV two-drug regimen approved in the US.
(CercleFinance.com) - GlaxoSmithKline said on Wednesday that a combination of two drugs has been approved in the US for the maintenance treatment of virologically suppressed HIV-1 infection.
The FDA decision is based upon data from two phase III trials which showed the regimen achieved non-inferior viral suppression at 48 weeks compared with a three-or-four drug regimen, GSK said..
The approved combination, named "Juluca," is a two-drug regimen comprising ViiV Healthcare's dolutegravir and Janssen's rilpivirine.
ViiV Healthcare, a drugmaker that specialises in HIV, is majority owned by GlaxoSmithKline, with Pfizer and Shionogi as other shareholders.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The FDA decision is based upon data from two phase III trials which showed the regimen achieved non-inferior viral suppression at 48 weeks compared with a three-or-four drug regimen, GSK said..
The approved combination, named "Juluca," is a two-drug regimen comprising ViiV Healthcare's dolutegravir and Janssen's rilpivirine.
ViiV Healthcare, a drugmaker that specialises in HIV, is majority owned by GlaxoSmithKline, with Pfizer and Shionogi as other shareholders.
Copyright (c) 2017 CercleFinance.com. All rights reserved.